Last reviewed · How we verify
NCT07201740
The Effectiveness of Leap Motion-Based Virtual Reality in the Rehabilitation of Flexor Tendon Injuries of the Hand
NA trial testing Leap Motion-based Virtual Reality Therapy in Flexor Tendon Injuries of the Hand (Zones II-V) in 66 participants. Not yet recruiting.
1 February 2026
Quick facts
| Lead sponsor | Kocaeli University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 1 October 2025 |
| Primary completion | 1 February 2026 |
| Estimated completion | 1 February 2026 |
Drugs / interventions tested
- Leap Motion-based Virtual Reality Therapy
- Active Comparator - Routine Rehabilitation Only
Conditions studied
- Flexor Tendon Injuries of the Hand (Zones II-V) — all drugs for Flexor Tendon Injuries of the Hand (Zones II-V) →
Sponsor
Kocaeli University
Who can join
Adults 18 to 65, any sex, with Flexor Tendon Injuries of the Hand (Zones II-V). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized controlled clinical trial aims to evaluate the effectiveness of a Leap Motion-based virtual reality rehabilitation program in patients who underwent surgical repair for flexor tendon injuries of the hand (zones II-V). A total of 66 participants, aged 18-65 years and at least 5 weeks postoperative, will be randomly assigned to two groups: the intervention group will receive routine hand rehabilitation plus Leap Motion-based virtual reality therapy for 20 minutes per day, 5 days per week, for 4 weeks; while the control group will continue routine hand rehabilitation only. Outcomes will include joint range of motion measured with a goniometer, pain intensity assessed with a Visual Analog Scale (VAS), grip strength measured with a Jamar dynamometer, and functional outcomes assessed using the QuickDASH questionnaire. The primary endpoint is the change in range of motion, grip strength, and QuickDASH score from baseline to post-treatment. Secondary endpoints include changes in upper extremity function and pain tolerance. All interventions will be delivered under therapist supervision. This study is expected to provide evidence on whether integrating Leap Motion-based virtual reality into conventional rehabilitation improves clinical outcomes after flexor tendon repair.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07201740
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Kocaeli University trials
Trials by the same sponsor.
- NCT06737887 — The Effect of Preoperative Stoma Simulation on Anxiety and Postoperative Adaptation · NA · recruiting
- NCT07483593 — Baseline Gastric Volume in Diabetic vs Non-Diabetic Patients · not yet recruiting
- NCT07536659 — Evaluation of Serum Autophagic Biomarkers in the Acute Response to Walking and Cycling in Healthy Male Individuals · enrolling by invitation
- NCT07482696 — Electromyographic Biofeedback Therapy in Patients With Dyssynergic Defecation · NA · not yet recruiting
- NCT07497945 — Optic Nerve Sheath Diameter for Predicting Post-Dural Puncture Headache in Cesarean Section Patients · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07201740 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kocaeli University
- Last refreshed: 1 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07201740.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing